Osama Rahma
Medical Oncology · Boston, MANPI 1730172149
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,024 of the $29,722 with a category attached, or 60.6%. 8 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 29.8% of the total. Reporting peaked in 2019 at $18,837 and has fallen 73.5% since, to $4,999 in 2021.
Across 32 payments — averaging $928.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$9K
- Genentech, Inc.$8K
- Swedish Orphan Biovitrum AB$5K
- GSK$3K
- Bayer$2K
- Boehringer Ingelheim RCV GmbH & Co KG$2K
- plus $1K from 2 others
Across 1,188 payments — averaging $3744.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.7M
- Incyte Corporation$863K
- Macrogenics, Inc.$324K
- Novartis$192K
- Roche Products Limited$174K
- Amgen$107K
- plus $119K from 3 others
What the payments were for
- Consulting fees$18,02461%
- Speaking & faculty fees$6,87923%
- Travel & lodging$3,46112%
- Food & beverage$1,3595%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 13 | $8,845 |
| Genentech, Inc. | 7 | $7,925 |
| Swedish Orphan Biovitrum AB | 2 | $4,831 |
| GSK | 1 | $3,399 |
| Bayer | 3 | $2,017 |
| Boehringer Ingelheim RCV GmbH & Co KG | 1 | $1,600 |
| Hoffmann-la Roche Limited | 4 | $1,055 |
| E.r. Squibb & Sons, L.L.C. | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TECENTRIQ$14,761
- Avastin$7,882
- Kineret$4,800
- Non-Covered Product$2,864
How this compares
$29,722 in reported general payments places this provider in the 70th percentile of 308 medical oncology providers in Massachusetts.
Other medical oncology in Boston
- George DemetriBoston$1.6M
- Keith FlahertyBoston$932K
- Alicia MorgansBoston$690K
- Pasi Antero JanneBoston$458K
- Robert HaddadBoston$451K
- Irene GhobrialBoston$431K
- Joaquin Bellmunt MolinsBoston$415K
- Jeremy AbramsonBoston$334K
- Justin GainorBoston$324K
- Narjust FlorezBoston$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.